Inograft is developing targeted biologic conditioning to replace toxic chemotherapy and radiation in hematopoietic stem cell transplantation (HSCT). This approach aims to make curative HSCT safer, more precise, and broadly accessible for treating various diseases. The company seeks to unlock the full potential of stem-cell and gene-based medicine by removing current treatment barriers.
Funding
Funding not disclosed
Founders
Product
Problem
Hematopoietic stem cell transplantation (HSCT) relies on conditioning regimens that often involve high doses of chemotherapy or radiation, leading to significant toxicity and long-term side effects in patients. These harsh conditioning methods are used to eliminate the patient's existing hematopoietic system to prevent rejection of the donor stem cells. The genotoxic nature of these treatments limits their applicability, especially in vulnerable populations.
Solution
Inograft Biotherapeutics is developing non-genotoxic conditioning regimens for HSCT to improve the safety and efficacy of stem cell therapies. Their approach aims to selectively deplete the recipient's hematopoietic stem cells without causing the broad systemic toxicity associated with traditional chemotherapy or radiation. By using targeted therapies, Inograft seeks to create a more tolerable environment for donor stem cell engraftment, reducing the risk of complications and improving long-term outcomes for patients undergoing HSCT. This novel conditioning strategy has the potential to expand the use of stem cell transplantation to a wider range of patients, including those who are currently ineligible due to age or comorbidities.
Target Audience
The primary target audience includes patients with hematological malignancies or other conditions requiring hematopoietic stem cell transplantation, as well as hematologists and oncologists seeking safer and more effective conditioning regimens.
Features
- Development of novel, non-genotoxic conditioning agents for hematopoietic stem cell transplantation
- Targeted depletion of recipient hematopoietic stem cells to prevent graft rejection
- Reduced systemic toxicity compared to traditional chemotherapy or radiation-based conditioning
- Improved safety profile, potentially expanding HSCT eligibility to a broader patient population